Americas Cancer Biological Therapy Market Highlight

Americas Cancer Biological therapy market is expected to grow at a 7.20% CAGR and to reach USD 104788.96 Million in coming future. There are number of different types of treatment available in the market like chemotherapy, radiotherapy and different drugs therapy, but every therapy has its minor or major side effects. Biological therapies may overcome the side effects like hair loss, weakened immune system which are caused by the other treatment methods. Success rate of all the therapies are same but biological therapy causes less side effects. Cancer can only be cure during 1st stage with a chances of approximately 40-50%.

Biological therapy involves treatment with the help of living organism. Many biological therapy are available for the treatment of cancer. Gene therapy has got a special attention in last few year. Many development and research are been carried out in this field and it can be a better option for the treatment of the cancer. According to National Cancer Institute, 14 million people are suffering from cancer in 2014 which is expected to increase upto 19 million till 2024. The major driving factor for cancer biological therapy market are introduction of new and better antibody, increasing incidence of cancer and less side effect of biological therapy over other optional therapy.

Segmentation

Americas Cancer Biological Therapy market has been segmented on the basis of-

• By types which comprises of monoclonal antibodies (Naked monoclonal antibodies, Conjugated monoclonal antibodies, other), interferons, interleukins, cancer growth inhibitors (Tyrosine kinase inhibitors, mTOR inhibitors and Proteasome inhibitors), gene therapy, colony-stimulating factors, targeted therapy, cancer vaccines and others.


• On the basis of end user, market is segmented into hospitals & clinics, cancer research centers, laboratories and others.


• And on the basis of Region market is segmented as US, Canada and Rest of America.